Focus on Myeloid Malignancies (Volume 5, Issue 6.1)

May 2019 Special Edition

Volume 5, Issue 6.1

This supplement features FDA updates for the treatment of myeloid malignancies, new questions in acute myeloid leukemia, and more.

Table of Contents

Newly Approved Drugs

The Year in FDA Approvals

Wednesday, May 1st, 2019
In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including the first treatment...


CMML: A Unique Overlap Syndrome Receiving Increased Attention

Wednesday, May 1st, 2019
For many years, chronic myelomonocytic leukemia (CMML) has been treated as a form of myelodysplastic syndrome (MDS), despite its unique clinical and biological characteristics. “Everyone...

New Treatment Options Lead to New Questions in Acute Myeloid Leukemia

Wednesday, May 1st, 2019
For the past 40 years, the standard remission induction treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive...

In the Literature

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

Wednesday, May 1st, 2019
A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...

CHIP-Associated Mutations Linked With Comorbidities in MDS

Wednesday, May 1st, 2019
The presence of clonal hematopoiesis of indeterminate potential (CHIP) mutations, particularly DNMT3A and JAK2 mutations, was associated with a higher likelihood of prior myocardial...

Meeting News

On location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Wednesday, May 1st, 2019
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...
On location

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Wednesday, May 1st, 2019
Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...
On location

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Wednesday, May 1st, 2019
Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...